Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 1.00 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.89 |
| ▸ | LDHB | P07195 | 4/20 | 0.43 |
| ▸ | TERF2IP | Q9NYB0 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | NPY4R | P50391 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | TERF2 | Q15554 | 1/20 | 0.35 |
| ▸ | F11 | P03951 | 2/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | STAT1 | P42224 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31066574 | 1.00 | KDM1A (1.00) | KDM1ARCOR1LDHBTERF2IPESR1 | |
| SCHEMBL18902532 | 1.00 | KDM1A (1.00) | KDM1ARCOR1LDHBTERF2IPESR1 | |
| SCHEMBL49226 | 1.00 | KDM1A (1.00) | KDM1ARCOR1LDHBTERF2IPESR1 | |
| SCHEMBL29394303 | 0.99 | KDM1A (0.99) | KDM1ARCOR1LDHBTERF2IPESR1 | |
| SCHEMBL25641510 | 0.99 | KDM1A (0.99) | KDM1ARCOR1LDHBTERF2IPESR1 | |
| SCHEMBL21474097 | 0.99 | KDM1A (0.99) | KDM1ARCOR1LDHBTERF2IPESR1 | |
| SCHEMBL14845813 | 0.99 | KDM1A (0.99) | KDM1ARCOR1LDHBTERF2IPESR1 | |
| SCHEMBL21474060 | 0.98 | KDM1A (0.96) | KDM1ARCOR1LDHBTERF2IPESR1 | |
| SCHEMBL24437319 | 0.98 | KDM1A (0.96) | KDM1ARCOR1LDHBTERF2IPESR1 | |
| SCHEMBL691747 | 0.98 | KDM1A (0.96) | KDM1ARCOR1LDHBTERF2IPESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630446-A1 | ENGINEERED SWITCHES FOR IMMUNE CELL ACTIVITY AND METHODS OF USE THEREOF | Dynamic Cell Therapies, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| EP-4630043-A1 | IMMUNE-ACTIVATING COMPLEXES | Dynamic Cell Therapies, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| US-20250241979-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2025-07-31 | — | — | US | claimed |
| US-12357657-B2 | Silver-/gold-compounds and methods thereof | THE UNIVERSITY OF HONG KONG (HK) | 2025-07-15 | — | — | US | claimed |
| WO-2024123836-A1 | IMMUNE-ACTIVATING COMPLEXES | DYNAMIC CELL THERAPIES, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| WO-2024123835-A1 | ENGINEERED SWITCHES FOR IMMUNE CELL ACTIVITY AND METHODS OF USE THEREOF | DYNAMIC CELL THERAPIES, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| CN-118090979-A | Method for measuring blood concentration of polymyxin E sodium mesylate and colistin in human plasma based on LC-MS/MS | 华中科技大学同济医学院附属同济医院 | 2024-05-28 | — | — | CN | claimed |
| CN-117425727-A | Variants of C-glucosyltransferase and uses thereof | 韩国科学技术院 | 2024-01-19 | — | — | CN | claimed |
| CN-117120040-A | Nanoparticle for oral administration of bioactive substance and method for preparing same | SNJ制药有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-116660415-A | Method for measuring colistin medicine residues in lettuce by liquid chromatography mass spectrometry | 贵州大学 | 2023-08-29 | — | — | CN | claimed |
| CN-114891678-B | Bacillus polymyxa CPL258 and screening and application thereof | 淮阴工学院 | 2023-08-22 | — | — | CN | claimed |
| US-20220313776-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2022-10-06 | — | — | US | claimed |
| US-20220296639-A1 | SILVER-/GOLD-COMPOUNDS AND METHODS THEREOF | UNIV HONG KONG (HK) | 2022-09-22 | — | — | US | claimed |
| CN-114891678-A | Bacillus polymyxa CPL258 and screening and application thereof | 淮阴工学院 | 2022-08-12 | — | — | CN | claimed |
| US-11406683-B2 | Compounds and therapeutics uses thereof | Centauri Therapeutics Limited (GB/GB) (GB) | 2022-08-09 | — | — | US | claimed |
| US-20220184173-A1 | STABLE PHARMACEUTICAL FORMULATIONS OF PEPTIDE AND PROTEIN DRUGS | EMPHASCIENCE INC (US) | 2022-06-16 | — | — | US | claimed |
| US-20220162262-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2022-05-26 | — | — | US | claimed |
| CN-114258308-A | Silver/gold compounds and methods thereof | 香港大学 | 2022-03-29 | — | — | CN | claimed |
| EP-3947417-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB) | 2022-02-09 | — | — | EP | claimed |
| EP-3773505-B1 | METHODS FOR CONTINUOUS MANUFACTURE OF LIPOSOMAL DRUG PRODUCTS | INSMED INC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12601740-B2 | Method and kit for identifying antimicrobial agents and effective concentrations thereof | COBIO DIAGNOSTICS INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12588675-B2 | Synergistic antibacterial activity of medium polarity oils in combination with antibacterial agents on bacterial biofilms | SMITH & NEPHEW, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12569534-B2 | Therapeutic nanoparticles by coacervate complexation and their use for treating bacteria | ACADEMIA SINICA (TW) | 2026-03-10 | — | — | US | disclosed |
| US-20260048168-A1 | WOUND TREATMENT SYSTEM | KIMMERLING HOLDINGS GROUP LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250367164-A1 | THERAPEUTIC COMPOSITIONS FOR SKIN DISORDERS AND WOUND REPAIR | UNIV MIAMI (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250352655-A1 | THERAPEUTIC ANNEXIN-DRUG CONJUGATES AND METHODS OF USE | UNIV OKLAHOMA (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250325481-A1 | METHODS FOR CONTINUOUS MANUFACTURE OF LIPOSOMAL DRUG PRODUCTS | INSMED INCORPORATED (US) | 2025-10-23 | — | — | US | disclosed |
| EP-3717033-B1 | FIBRIN PARTICLES AND METHODS OF MAKING THE SAME | UNIV NORTH CAROLINA STATE (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4630446-A1 | ENGINEERED SWITCHES FOR IMMUNE CELL ACTIVITY AND METHODS OF USE THEREOF | Dynamic Cell Therapies, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-4630043-A1 | IMMUNE-ACTIVATING COMPLEXES | Dynamic Cell Therapies, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| US-12440450-B2 | Fibrin particles and methods of making the same | NORTH CAROLINA STATE UNIVERSITY (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250297220-A1 | IMMUNE-ACTIVATING COMPLEXES | DYNAMIC CELL THERAPIES, INC. | 2025-09-25 | — | — | US | disclosed |
| US-20250297022-A1 | ENGINEERED SWITCHES FOR IMMUNE CELL ACTIVITY AND METHODS OF USE THEREOF | DYNAMIC CELL THERAPIES, INC. | 2025-09-25 | — | — | US | disclosed |
| US-20250289878-A1 | SURFACE-MODIFIED EXOSOMES AND METHODS OF USE | UNIV OKLAHOMA (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250241979-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2025-07-31 | — | — | US | disclosed |
| US-12357657-B2 | Silver-/gold-compounds and methods thereof | THE UNIVERSITY OF HONG KONG (HK) | 2025-07-15 | — | — | US | disclosed |
| US-20250205316-A1 | COLLOIDAL FIBRIN NANOPARTICLE COMPOSITIONS AND USES | NORTH CAROLINA STATE UNIVERSITY | 2025-06-26 | — | — | US | disclosed |
| US-20250170105-A1 | ASSOCIATION WITH ANTIBIOTIC ACTIVITY, PHARMACEUTICAL COMPOSITIONS CONTAINING IT AND THEIR USE IN THE TREATMENT OF INFECTIONS | VETAGRO INTERNATIONAL S.R.L. (IT) | 2025-05-29 | — | — | US | disclosed |
| US-12290600-B2 | Methods for continuous manufacture of liposomal drug products | INSMED INCORPORATED (US) | 2025-05-06 | — | — | US | disclosed |
| US-20250065020-A1 | BIOCOMPATIBLE METAL ION-CHITOSAN HYDROGELS WITH ANTIMICROBIAL PROPERTIES | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES | 2025-02-27 | — | — | US | disclosed |
| EP-4499053-A1 | ASSOCIATION WITH ANTIBIOTIC ACTIVITY, PHARMACEUTICAL COMPOSITIONS CONTAINING IT AND THEIR USE IN THE TREATMENT OF INFECTIONS | Vetagro International S.r.l. (IT) | 2025-02-05 | — | — | EP | disclosed |
| US-20250008961-A1 | PAENIBACILLUS STRAINS PRODUCING LOW AMOUNTS OF DAB COMPRISING COMPOUNDS | BASF SE (DE) | 2025-01-09 | — | — | US | disclosed |
| US-12178889-B2 | Gold nanoparticle-ligand conjugates and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2024-12-31 | — | — | US | disclosed |
| US-12178790-B2 | Antibacterial compound isolated from Psiloxylon mauritianum and its derivatives | SORRES, Jonathan (FR) | 2024-12-31 | — | — | US | disclosed |
| US-12171779-B2 | Regulated drug delivery via controlled degradable chondroitin sulfate particles | UNIVERSITY OF SOUTH FLORIDA (US) | 2024-12-24 | — | — | US | disclosed |
| EP-4477272-A2 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | Monash University (AU) | 2024-12-18 | — | — | EP | disclosed |
| US-12146004-B2 | Polymyxin compounds and uses thereof | SPERO THERAPEUTICS, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| US-12138292-B2 | Compounds and therapeutics uses thereof | Centauri Therapeutics Limited (GB/GB) (GB) | 2024-11-12 | — | — | US | disclosed |
| CN-118908888-A | Catechol compound and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2024-11-08 | — | — | CN | disclosed |
| WO-2024226763-A1 | BROAD-SPECTRUM ANTIBIOTIC HYBRIDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT INFECTIONS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-10-31 | — | — | WO | disclosed |
| CN-118871100-A | Antiviral therapeutic agent and use thereof | 西拉治疗公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-4444323-A1 | ANTI-VIRAL THERAPEUTIC AGENTS AND USES THEREOF | Cila Therapeutic Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4436387-A1 | PAENIBACILLUS STRAINS PRODUCING LOW AMOUNTS OF DAB COMPRISING COMPOUNDS | BASF SE (DE) | 2024-10-02 | — | — | EP | disclosed |
| US-20240307333-A1 | ANTI-VIRAL THERAPEUTIC AGENTS AND USES THEREOF | Cila Therapeutics Inc. (US) | 2024-09-19 | — | — | US | disclosed |
| US-20240285586-A1 | METHODS FOR TREATING BACTERIAL CELL POPULATIONS | UNIV HONG KONG POLYTECHNIC (CN) | 2024-08-29 | — | — | US | disclosed |
| EP-3126376-B1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | UNIV MONASH (AU) | 2024-08-21 | — | — | EP | disclosed |
| WO-2024153108-A1 | CHELATING COMPLEX MICELLE PRESENTING ANTIMICROBIAL ACTIVITY AGAINST GRAM-NEGATIVE BACTERIA AND METHOD FOR USING THEREOF | ORIGINAL BIOMEDICALS CO., LTD. (CN) | 2024-07-25 | — | — | WO | disclosed |
| EP-3356387-B1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | UNIV MONASH (AU) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024123836-A1 | IMMUNE-ACTIVATING COMPLEXES | DYNAMIC CELL THERAPIES, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024123835-A1 | ENGINEERED SWITCHES FOR IMMUNE CELL ACTIVITY AND METHODS OF USE THEREOF | DYNAMIC CELL THERAPIES, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| CN-118090979-A | Method for measuring blood concentration of polymyxin E sodium mesylate and colistin in human plasma based on LC-MS/MS | 华中科技大学同济医学院附属同济医院 | 2024-05-28 | — | — | CN | disclosed |
| CN-118090979-A | Method for measuring blood concentration of polymyxin E sodium mesylate and colistin in human plasma based on LC-MS/MS | 华中科技大学同济医学院附属同济医院 | 2024-05-28 | — | — | CN | disclosed |
| CN-118078744-A | Polymyxin E sodium mesylate injection and preparation process thereof | 南京正科医药股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-108472258-B | Formulations/compositions comprising BTK inhibitors | 詹森药业有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20240151719-A1 | METHOD AND KIT FOR IDENTIFYING ANTIMICROBIAL AGENTS AND EFFECTIVE CONCENTRATIONS THEREOF | COBIO DIAGNOSTICS INC. | 2024-05-09 | — | — | US | disclosed |
| CN-117956989-A | Method for treating bacterial cell populations | 香港理工大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-117794932-A | Pyridopyrimidine derivatives useful as WEE1 kinase inhibitors | 阿普里治疗股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117441022-A | Sequential electroporation method | 美克斯细胞有限公司 | 2024-01-23 | — | — | CN | disclosed |
| EP-4305423-A1 | METHOD AND KIT FOR IDENTIFYING ANTIMICROBIAL AGENTS AND EFFECTIVE CONCENTRATIONS THEREOF | Cobio Diagnostics Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230414527-A1 | FIBRIN PARTICLES AND METHODS OF MAKING THE SAME | NORTH CAROLINA STATE UNIVERSITY | 2023-12-28 | — | — | US | disclosed |
| CN-110022896-B | Novel compounds and therapeutic uses thereof | 森陶里治疗有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-117244076-A | Conjugates comprising self-degrading groups and methods related thereto | 乐高化学生物科学股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20230345938-A1 | SYNERGISTIC ANTIBACTERIAL ACTIVITY OF MEDIUM POLARITY OILS IN COMBINATION WITH ANTIBACTERIAL AGENTS ON BACTERIAL BIOFILMS | SMITH & NEPHEW, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230340026-A1 | COMPOUNDS | NEW PHARMA LICENCE HOLDINGS LTD (MT) | 2023-10-26 | — | — | US | disclosed |
| US-11786477-B2 | Fibrin particles and methods of making the same | NORTH CAROLINA STATE UNIVERSITY (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2023187644-A1 | ASSOCIATION WITH ANTIBIOTIC ACTIVITY, PHARMACEUTICAL COMPOSITIONS CONTAINING IT AND THEIR USE IN THE TREATMENT OF INFECTIONS | VETAGRO INTERNATIONAL S.R.L. (IT) | 2023-10-05 | — | — | WO | disclosed |
| US-20230301905-A1 | INHALABLE THERAPEUTIC AGENTS | CILA THERAPEUTIC INC (US) | 2023-09-28 | — | — | US | disclosed |
| CN-116660415-A | Method for measuring colistin medicine residues in lettuce by liquid chromatography mass spectrometry | 贵州大学 | 2023-08-29 | — | — | CN | disclosed |
| CN-114891678-B | Bacillus polymyxa CPL258 and screening and application thereof | 淮阴工学院 | 2023-08-22 | — | — | CN | disclosed |
| WO-2023137312-A1 | BIOCOMPATIBLE METAL ION-CHITOSAN HYDROGELS WITH ANTIMICROBIAL PROPERTIES | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20230218529-A1 | METHODS FOR CONTINUOUS MANUFACTURE OF LIPOSOMAL DRUG PRODUCTS | INSMED INCORPORATED | 2023-07-13 | — | — | US | disclosed |
| EP-4203928-A1 | INHALABLE THERAPEUTIC AGENTS | Cila Therapeutic Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116390726-A | Inhalable therapeutic agents | 希拉治疗公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2023107996-A1 | ANTI-VIRAL THERAPEUTIC AGENTS AND USES THEREOF | CILA THERAPEUTIC INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230172970-A1 | REGULATED DRUG DELIVERY VIA CONTROLLED DEGRADABLE CHONDROITIN SULFATE PARTICLES | UNIVERSITY OF SOUTH FLORIDA | 2023-06-08 | — | — | US | disclosed |
| CN-116203173-A | Method for simultaneously measuring concentration of polymyxin E1 and polymyxin E2 in human serum based on LC-MS/MS method | 中国人民解放军空军军医大学 | 2023-06-02 | — | — | CN | disclosed |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-11646117-B2 | Matrix factorization of antibiogram metadata | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2023-05-09 | — | — | US | disclosed |
| US-11641856-B2 | Synergistic antibacterial activity of medium polarity oils in combination with antibacterial agents on bacterial biofilms | SMITH & NEPHEW, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-1909759-B2 | SUSTAINED RELEASE OF ANTIINFECTIVE AMINOGLYCOSIDES | INSMED INC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20230130754-A1 | SURFACE-MODIFIED EXOSOMES AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2023-04-27 | — | — | US | disclosed |
| CN-116018353-A | anti-ROR-2 antibodies and methods of use | 加利福尼亚大学董事会 | 2023-04-25 | — | — | CN | disclosed |
| US-20230103789-A1 | SEQUENTIAL ELECTROPORATION METHODS | MAXCYTE, INC. (US) | 2023-04-06 | — | — | US | disclosed |
| US-11608356-B1 | Functional ligands to colistin | Base Pair Biotechnologies, Inc. (US) | 2023-03-21 | — | — | US | disclosed |
| US-20230062900-A1 | NEW ANTIBACTERIAL COMPOUND ISOLATED FROM PSILOXYLON MAURITIANUM AND ITS DERIVATIVES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2023-03-02 | — | — | US | disclosed |
| US-11571386-B2 | Methods for continuous manufacture of liposomal drug products | INSMED INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
| US-20230008563-A1 | SUSTAINED RELEASE OF ANTIINFECTIVES | INSMED INCORPORATED (US) | 2023-01-12 | — | — | US | disclosed |
| WO-2022257105-A1 | METHODS FOR TREATING BACTERIAL CELL POPULATIONS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2022-12-15 | — | — | WO | disclosed |
| US-20220395578-A1 | THERAPEUTIC ANNEXIN-DRUG CONJUGATES AND METHODS OF USE | UNIV OKLAHOMA (US) | 2022-12-15 | — | — | US | disclosed |
| WO-2022232802-A1 | SEQUENTIAL ELECTROPORATION METHODS | MAXCYTE, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| US-20220313776-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2022-10-06 | — | — | US | disclosed |
| EP-3528830-B1 | POLYMYXIN-ALGINATE OLIGOMER CONJUGATES | ALGIPHARMA AS (NO) | 2022-10-05 | — | — | EP | disclosed |
| US-20220296639-A1 | SILVER-/GOLD-COMPOUNDS AND METHODS THEREOF | UNIV HONG KONG (HK) | 2022-09-22 | — | — | US | disclosed |
| WO-2022192208-A1 | METHOD AND KIT FOR IDENTIFYING ANTIMICROBIAL AGENTS AND EFFECTIVE CONCENTRATIONS THEREOF | COBIO DIAGNOSTICS INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| CN-217339582-U | Point-of-care drug delivery device | 建南德克公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114891678-A | Bacillus polymyxa CPL258 and screening and application thereof | 淮阴工学院 | 2022-08-12 | — | — | CN | disclosed |
| US-11406683-B2 | Compounds and therapeutics uses thereof | Centauri Therapeutics Limited (GB/GB) (GB) | 2022-08-09 | — | — | US | disclosed |
| US-11382884-B2 | Method for reducing lung infection | Respirion Pharmaceuticals Pty Ltd (CA) | 2022-07-12 | — | — | US | disclosed |
| US-20220192191-A1 | SYNERGISTIC ANTIBACTERIAL ACTIVITY OF MEDIUM POLARITY OILS IN COMBINATION WITH ANTIBACTERIAL AGENTS ON BACTERIAL BIOFILMS | SMITH & NEPHEW, INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-20220184173-A1 | STABLE PHARMACEUTICAL FORMULATIONS OF PEPTIDE AND PROTEIN DRUGS | EMPHASCIENCE INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220162262-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2022-05-26 | — | — | US | disclosed |
| WO-2022101267-A2 | COMPOSITIONS FOR DELIVERY OF AN ADSORBENT | DA VOLTERRA (FR) | 2022-05-19 | — | — | WO | disclosed |
| WO-2022101269-A1 | FORMULATIONS AND DOSAGE REGIMEN FOR ORAL DELIVERY OF ADSORBENTS IN THE GUT | DA VOLTERRA (FR) | 2022-05-19 | — | — | WO | disclosed |
| WO-2022084550-A1 | COMPOSITIONS FOR USE IN THE TREATMENT OR PREVENTION OF DYSBIOSIS | DA VOLTERRA (FR) | 2022-04-28 | — | — | WO | disclosed |
| US-20220117893-A1 | INHALABLE THERAPEUTIC AGENT | THE BLUE GROUP LLC | 2022-04-21 | — | — | US | disclosed |
| CN-114258308-A | Silver/gold compounds and methods thereof | 香港大学 | 2022-03-29 | — | — | CN | disclosed |
| CN-108350034-B | Antimicrobial polymyxin derived compounds | 莫纳什大学 | 2022-03-11 | — | — | CN | disclosed |
| WO-2022047047-A1 | INHALABLE THERAPEUTIC AGENTS | CILA THERAPEUTIC INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| CN-114099840-A | Point-of-care drug delivery devices and methods | 建南德克公司 | 2022-03-01 | — | — | CN | disclosed |
| EP-3947417-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB) | 2022-02-09 | — | — | EP | disclosed |
| US-20190315806-A1 | POLYMYXIN DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CAMS (CN) | 2019-10-17 | — | — | US | disclosed |
| US-20190315806-A1 | POLYMYXIN DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CAMS (CN) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (25 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569534-B2 | Therapeutic nanoparticles by coacervate complexation and their use for treating bacteria | PHOSPHO1, CUTA, PCTP | KDM1A 4178/4885RCOR1 4303/4885LDHB 935/4885 |
| US-20230172970-A1 | REGULATED DRUG DELIVERY VIA CONTROLLED DEGRADABLE CHONDROITIN SULFATE PARTICLES | CD44, CSGALNACT1, ALG1 | KDM1A 2848/4885RCOR1 3863/4885LDHB 2073/4885 |
| US-20230301905-A1 | INHALABLE THERAPEUTIC AGENTS | MUC1, CMA1, SERPINB1 | KDM1A 4412/4885RCOR1 4231/4885LDHB 1135/4885 |
| US-20220117893-A1 | INHALABLE THERAPEUTIC AGENT | LPO, LIPA, SMPD1 | KDM1A 4158/4885RCOR1 4160/4885LDHB 432/4885 |
| US-12601740-B2 | Method and kit for identifying antimicrobial agents and effective concentrations thereof | MYD88, TNFSF11, TNF | KDM1A 4264/4885RCOR1 3655/4885LDHB 2450/4885 |
| US-20230008563-A1 | SUSTAINED RELEASE OF ANTIINFECTIVES | LIPA, CFTR, SLC47A1 | KDM1A 3861/4885RCOR1 963/4885LDHB 1859/4885 |
| US-12357657-B2 | Silver-/gold-compounds and methods thereof | MCRS1, SLC11A2, ABCC1 | KDM1A 4564/4885RCOR1 3371/4885LDHB 734/4885 |
| US-11406683-B2 | Compounds and therapeutics uses thereof | MYD88, MAVS, CD47 | KDM1A 4104/4885RCOR1 4159/4885LDHB 1352/4885 |
| US-20190315806-A1 | POLYMYXIN DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | NPEPPS, MYD88, MRPL21 | KDM1A 2143/4885RCOR1 1398/4885LDHB 2499/4885 |
| US-20230340026-A1 | COMPOUNDS | BCAT1, BCAT2, CCNT1 | KDM1A 3334/4885RCOR1 2022/4885LDHB 522/4885 |
| US-20220313776-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | MAVS, MYD88, CD47 | KDM1A 4216/4885RCOR1 3890/4885LDHB 1565/4885 |
| US-12588675-B2 | Synergistic antibacterial activity of medium polarity oils in combination with antibacterial agents on bacterial biofilms | CUTA, DSG1, IL33 | KDM1A 2613/4885RCOR1 2580/4885LDHB 4734/4885 |
| US-20250367164-A1 | THERAPEUTIC COMPOSITIONS FOR SKIN DISORDERS AND WOUND REPAIR | DSC1, DSG1, CUTA | KDM1A 4505/4885RCOR1 3447/4885LDHB 2559/4885 |
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | KDM1A 4789/4885RCOR1 4863/4885LDHB 874/4885 |
| US-12138292-B2 | Compounds and therapeutics uses thereof | MYD88, MAVS, CD47 | KDM1A 4104/4885RCOR1 4159/4885LDHB 1352/4885 |
| US-12146004-B2 | Polymyxin compounds and uses thereof | BCAT1, BCAT2, PNISR | KDM1A 3577/4885RCOR1 3074/4885LDHB 988/4885 |
| US-20220296639-A1 | SILVER-/GOLD-COMPOUNDS AND METHODS THEREOF | MCRS1, SLC11A2, ABCC1 | KDM1A 4564/4885RCOR1 3371/4885LDHB 734/4885 |
| US-12171779-B2 | Regulated drug delivery via controlled degradable chondroitin sulfate particles | CD44, CSGALNACT1, ALG1 | KDM1A 2848/4885RCOR1 3863/4885LDHB 2073/4885 |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | KDM1A 4789/4885RCOR1 4863/4885LDHB 874/4885 |
| US-20230062900-A1 | NEW ANTIBACTERIAL COMPOUND ISOLATED FROM PSILOXYLON MAURITIANUM AND ITS DERIVATIVES | PNN, AAAS, MRPS35 | KDM1A 4168/4885RCOR1 4297/4885LDHB 3482/4885 |
| US-20240285586-A1 | METHODS FOR TREATING BACTERIAL CELL POPULATIONS | CD68, MMP8, CRYAB | KDM1A 1994/4885RCOR1 2643/4885LDHB 114/4885 |
| US-12178790-B2 | Antibacterial compound isolated from Psiloxylon mauritianum and its derivatives | AAAS, PNN, MRPL9 | KDM1A 4087/4885RCOR1 4421/4885LDHB 3381/4885 |
| US-20220162262-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | MAVS, MYD88, CD47 | KDM1A 4412/4885RCOR1 3851/4885LDHB 1356/4885 |
| US-20250241979-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | MAVS, MYD88, CD47 | KDM1A 4216/4885RCOR1 3890/4885LDHB 1565/4885 |
| US-20260048168-A1 | WOUND TREATMENT SYSTEM | QARS1, SETDB1, KDM1B | KDM1A 4/4885RCOR1 140/4885LDHB 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.